Financial PerformanceNyxoah raised €48.5M in capital through the issuance of new shares, extending the company’s cash runway to the beginning of 2026.
Market PotentialNyxoah estimates the target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market of approximately $10 billion.
Regulatory ProgressNyxoah announced the submission of the fourth and final module of its PMA application for Genio to the FDA, keeping the US approval and commercialization on track.